8-K: Aclarion Secures $1 Million in Convertible Preferred Stock and Warrants Financing

Aclarion, Inc. has entered into a securities purchase agreement for a $1 million financing through the issuance of convertible preferred stock and warrants.

Summary

• Aclarion, Inc. has secured $1 million in gross proceeds through a securities purchase agreement.
• The company issued 1,000 shares of Series C convertible preferred stock at $1,000 per share.
• The Series C preferred stock is convertible into common stock at an initial price of $0.1759 per share.
• Warrants to purchase 5,685,049 shares of common stock were also issued with an initial exercise price of $0.1759 per share and a 5.5 year term.
• The proceeds will be used for general corporate purposes.
• The Series C preferred stock ranks senior to common stock regarding dividends and liquidation rights.
• Holders of the Series C preferred stock are entitled to a 10% annual dividend, payable quarterly, with the option for the company to pay in additional shares of common stock.
• The company can also capitalize the dividends by adding them to the stated value of the preferred stock.
• The conversion price of the preferred stock is subject to anti-dilution adjustments.
• Upon certain triggering events, the dividend rate increases to 18% and the conversion price is adjusted to an alternate conversion price.
• The company has the right to redeem the preferred shares at a 25% premium to the greater of the amount of shares being redeemed and the equity value of the underlying common stock.
• Upon liquidation, holders of the Series C preferred stock are entitled to receive in cash the Black Scholes value of their warrants plus 125% of the liquidation value or the amount they would receive if they converted immediately prior to the liquidation.

Sentiment

Score: 5

Explanation: The document outlines a financing agreement, which is a neutral event. While it provides capital, it also introduces potential dilution and increased costs. The sentiment is therefore moderately neutral.

Positives

• The financing provides Aclarion with $1 million in gross proceeds for general corporate purposes.
• The Series C preferred stock has a senior ranking to common stock regarding dividends and liquidation rights.
• The conversion price of the preferred stock is subject to anti-dilution adjustments, protecting investors from dilution.
• The company has agreed to file a registration statement for the resale of the common stock issuable upon conversion of the preferred stock or exercise of the warrants within 30 days of the closing.

Negatives

• The conversion price of the preferred stock is subject to anti-dilution adjustments, which could result in further dilution of existing shareholders.
• The company has the option to pay dividends in additional shares of common stock, which could further dilute existing shareholders.
• The company has the right to redeem the preferred shares at a 25% premium, which could be a significant cost to the company.

Risks

• The conversion price of the preferred stock is subject to anti-dilution adjustments, which could result in further dilution of existing shareholders.
• The company has the option to pay dividends in additional shares of common stock, which could further dilute existing shareholders.
• The company has the right to redeem the preferred shares at a 25% premium, which could be a significant cost to the company.
• The company's past working capital deficiency, stockholders deficit and recurring losses from operations raise substantial doubt about its ability to continue as a going concern.

Future Outlook

The company intends to use the proceeds from the sale of the securities for general corporate purposes.

Industry Context

This financing is a common method for small-cap companies to raise capital. The terms of the financing, including the conversion price, exercise price, and dividend rate, are typical for this type of transaction.

Comparison to Industry Standards

• The use of convertible preferred stock and warrants is a common financing method for small-cap companies, particularly those in the biotechnology or pharmaceutical sectors.
• The 10% dividend rate on the preferred stock is relatively high, which may be attractive to investors seeking income.
• The anti-dilution provisions are standard for this type of financing, protecting investors from dilution.
• The 5.5 year term for the warrants is also typical for this type of transaction.
• The conversion price and exercise price are set at a premium to the current market price, which is common in these types of financings.
• Comparable companies that have used similar financing structures include [list comparable companies if available].
• The terms of this financing are similar to other recent financings in the small-cap biotechnology sector, such as [list comparable financings if available].

Stakeholder Impact

• Shareholders may experience dilution due to the issuance of new shares of common stock upon conversion of the preferred stock and exercise of the warrants.
• Shareholders may also experience dilution if the company chooses to pay dividends in additional shares of common stock.
• The company's financial position may improve due to the infusion of capital.
• The company's ability to continue as a going concern may be improved due to the infusion of capital.

Next Steps

• The company will file a registration statement for the resale of the common stock issuable upon conversion of the preferred stock or exercise of the warrants within 30 days of the closing.
• The company will use the proceeds from the sale of the securities for general corporate purposes.

Key Dates

Keywords

convertible preferred stock, warrants, financing, securities purchase agreement, common stock, conversion price, exercise price, registration rights, anti-dilution, dividends